A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Clinical trial NCT02041260 · UNKNOWN

Trial details

NCT number: NCT02041260
Sponsor: Thomas Jefferson University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Differentiated Thyroid Cancer (DTC)Poorly Differentiated Thyroid Cancer

Start date: 2014-01-01
Primary completion: 2022-05-01
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.